Welcome Guest
Home > Clinical Breast Cancer > Volume 7 |  Issue 7 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  Buzdar AU. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc) 2004; 40:751-764.
    2.  Bowler J, Dukes M, Wakeling AE, et al. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51:3867-3873.
    3.  Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000; 7:17-28.
    4.  Howell A, Osborne CK, Robertson JF, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials. Cancer 2003; 98:229-238.
    5.  Abram P, Howell A, Robertson JF, Robertson JFR, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22:1605-1613.
    6.  Bartsch R, Steger GG, Wenzel C, et al. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 2005; 41:2655-2661.
    7.  Gips M, Simon SD, Steger GG, et al. Fulvestrant ('Faslodex'): clinical experience from the compassionate use programme. Cancer Treat Rev 2005; 31(2 suppl):S10-S16.
    8.  Franco S, Perez A, Tan-Chiu E, et al. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Breast Cancer Res T 2004; 88:103-108.
    9.  Petruzelka L, Zimovjanova M. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - results from an expanded access programme. Eur J Cancer Suppl 2004; 3:132-133.
    10.  Kleeberg U, Robertson JFR, Vergote I, et al. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res T 2003; 79:207-211.
    11.  Gorbunova VA, Howell A, Robertson JFR, et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res T 2005; 92:169-174.
    12.  Elledge RM, Howell A, Pippen J, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104:236-239.
    13.  Howell A, Quaresma Albano J, Robertson JF, Robertson JFR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20:3396-3403.
    14.  Mauriac L, Pippen JE, Quaresma Albano J, et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003; 39:1228-1233.
    15.  Jones SE, Osborne CK, Pippen J, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20:3386-3395.
    16.  Ingle JN, Rowland KM, Suman VJ, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006; 24:1052-1056.
    17.  Hawle H, Paridaens R, Perey L, Thörlimann B, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-69.
    18.  Chia S, Gradishar W, Piccart M, et al. on behalf of the EFECT writing committee. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Paper presented at: San Antonio Breast Cancer Symposium; December 14-16, 2006; San Antonio, TX. Available at: http://www.abstracts2view.com/sabcs06/view.php?nu=SABCS06L_1152. Accessed August 1, 2006..
    19.  Dodwell D, Pippen J. Time to response: comparison of fulvestrant and oral endocrine agents. Clin Breast Cancer 2006; 7:244-247.
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume 7
  •  Issue 7
    • Publication Date: April 2007


Evaluation of Fulvestrant in Clinical Practice: Use of an Electronic Data Registry


Elyse E. Lower, Benjamin T. Esparaz, Sally A. Garnett, James L. Wade III

Background: Most postmenopausal women with hormone receptor-positive advanced breast cancer eventually develop resistance to endocrine therapy, resulting in disease progression and the need for further treatment. Fulvestrant's distinct mode of action offers the potential to overcome tumor resistance to previous endocrine treatments. Patients and Methods: This observational, postmarketing, Web-based surveillance study collected“realworld” information on the use of, and the outcomes associated with, fulvestrant 250-mg-per month treatment of patients with advanced breast cancer in clinical practice. Results: A total of 213 postmenopausal patients with advanced breast cancer were enrolled from 34 practices throughout the United States. Of these, 200 patients (93.9%) had received previous endocrine therapy. Overall, 85.4% of patients had received previous aromatase inhibitor treatment for early breast cancer, advanced breast cancer, or both. In clinical practice, fulvestrant was most frequently administered as a second-line (46% of patients) or a third-line endocrine treatment (27.7% of patients) for advanced disease. Most patients who discontinued fulvestrant (55.1%) subsequently received cytotoxic chemotherapy. Fulvestrant treatment resulted in clinical benefit for 47.9% of patients; 58 patients (27.2%) exhibited an objective response, of whom 3 exhibited a complete response. The median time to response was 2.1 months, and the median duration of response was 7.6 months. At the time of analysis, 74.6% of patients hadexperienced disease progression; median time to progression was 4.7 months. Conclusion: These findings are similar to those reported in the clinical trial setting and confirm that fulvestrant has clinical activity after progression on previous endocrine therapy, including aromatase inhibitors.

Key words: Aromatase inhibitors, Estrogen receptor antagonists, Surveillance study, Treatment sequence


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. Pengeluaran SDY